Skip to content
stockresearch.app
VRTX/History

Vertex Pharmaceuticals (VRTX) valuation history

Above its usual range

As of

VRTX's EV/EBITDA of 25.2x is higher than 84% of its available weekly readings from the last five years.

EV/EBITDA weekly history12.6×18.8×25×31.3×Shading: 5-year middle halfMedian 21.4×25.2×202120232025
Share EV/EBITDA history
Preview embed

Chart by stockresearch.app. Reuse with credit under CC BY 4.0.

EV/EBITDA at year-end

Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.

VRTX year-end valuation history
Reading dateEV/EBITDA5-year rank
26.3×95%
UnavailableShort history
23.3×63%
15.2×5%
18.1×15%
20.3×4%
60.4×27%
59.5×7%
365.9×83%
UnavailableShort history

Loading related research…

About this history

What is VRTX's current EV/EBITDA?
VRTX's EV/EBITDA of 25.2x is higher than 84% of its available weekly readings from the last five years.
What is VRTX's five-year median EV/EBITDA?
The median, or middle weekly reading, is 21.4× over the last five years. Available history contains 818 weekly observations from Feb 21, 2011 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?
No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.

Source: SEC company filings and weekly market prices. Multiples use the previous twelve months of financial results. Updated .

Read the valuation methodology